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Agrin is a high-affinity binding protein of dystroglycan in
non-muscle tissue
Abstract
Agrin is a basement membrane-associated proteoglycan that induces the formation of postsynaptic
specializations at the neuromuscular junction. This activity is modulated by alternative splicing and is
thought to be mediated by receptors expressed in muscle fibers. An isoform of agrin that does not induce
postsynaptic specializations binds with high affinity to dystroglycan, a component of the
dystrophin-glycoprotein complex. Transcripts encoding this agrin isoform are expressed in a variety of
non-muscle tissues. Here, we analyzed the tissue distribution of agrin and dystroglycan on the protein
level and determined their binding affinities. We found that agrin is most abundant in lung, kidney, and
brain. Only a little agrin was detected in skeletal muscle, and no agrin was found in liver. Dystroglycan
was highly expressed in all tissues examined except in liver. In a solid-phase radioligand binding assay,
agrin bound to dystroglycan from lung, kidney, and skeletal muscle with a dissociation constant between
1.8 and 2.2 nM, while the affinity to brain-derived dystroglycan was 4.6 nM. In adult kidney and lung,
agrin co-purified and co-immunoprecipitated with dystroglycan, and both molecules were co-localized
in embryonic tissue. These data show that the agrin isoform expressed in non-muscle tissue is a
high-affinity binding partner of dystroglycan and they suggest that this interaction, like that between
laminin and dystroglycan, may be important for the mechanical integrity of the tissue.
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Agrin is a basement membrane-associated proteogly-
can that induces the formation of postsynaptic special-
izations at the neuromuscular junction. This activity is
modulated by alternative splicing and is thought to be
mediated by receptors expressed in muscle fibers. An
isoform of agrin that does not induce postsynaptic spe-
cializations binds with high affinity to dystroglycan, a
component of the dystrophin-glycoprotein complex.
Transcripts encoding this agrin isoform are expressed
in a variety of non-muscle tissues. Here, we analyzed the
tissue distribution of agrin and dystroglycan on the pro-
tein level and determined their binding affinities. We
found that agrin is most abundant in lung, kidney, and
brain. Only a little agrin was detected in skeletal mus-
cle, and no agrin was found in liver. Dystroglycan was
highly expressed in all tissues examined except in liver.
In a solid-phase radioligand binding assay, agrin bound
to dystroglycan from lung, kidney, and skeletal muscle
with a dissociation constant between 1.8 and 2.2 nM,
while the affinity to brain-derived dystroglycan was 4.6
nM. In adult kidney and lung, agrin co-purified and co-
immunoprecipitated with dystroglycan, and both mole-
cules were co-localized in embryonic tissue. These data
show that the agrin isoform expressed in non-muscle
tissue is a high-affinity binding partner of dystroglycan
and they suggest that this interaction, like that between
laminin and dystroglycan, may be important for the me-
chanical integrity of the tissue.
Agrin is a heparan sulfate proteoglycan that is required for
the induction and regeneration of pre- and postsynaptic spe-
cializations at neuromuscular junctions (NMJ1; Refs. 1 and 2).
When applied to cultured chick myotubes, agrin leads to the
formation of protein aggregates containing acetylcholine recep-
tors (AChRs), acetylcholinesterase, and several other mole-
cules that are also found at the neuromuscular junction in vivo
(3). The aggregating activity of agrin is strongly influenced by
alternative mRNA splicing at two sites, called A and B in chick
(y and z in rodents). While agrin isoforms that contain inserts
at these sites are highly active in an AChR aggregation assay,
an agrin isoform lacking the inserts, designated agrinA0B0, is
inactive (4–6). Agrin mRNA encoding isoforms with AChR-
aggregating activity are expressed in motor neurons, while
cells in non-nervous tissue synthesize agrin transcripts lacking
inserts at sites A and B (agrinA0B0; Refs. 4 and 7–12). Conse-
quently, agrin-like immunoreactivity is detected in numerous
non-neuronal tissues (13, 14).
In skeletal muscle and the electric organ of Torpedo califor-
nica, the major binding protein of agrin is a-dystroglycan (15–
18). a-Dystroglycan originates from a precursor protein that
becomes cleaved post-translationally giving rise to a-dystrogly-
can, a heavily glycosylated peripheral membrane protein that
binds to laminin and agrin, and the transmembrane protein
b-dystroglycan (19). Both molecules associate with several
other proteins to form the dystrophin-glycoprotein complex
(DGC; reviewed in Ref. 20). Mutations in genes that encode
different members of the DGC cause several muscular dystro-
phies (reviews: 21, 22), suggesting that the DGC links the
subsarcolemmal cytoskeleton and the muscle fiber’s basement
membrane to confer mechanical stability. Unlike some of the
other components of the DGC, dystroglycan is expressed in a
variety of tissues (19), and the recent observation that dystrogly-
can-deficient mice, which die early in development, fail to form a
functional Reichert’s membrane (23) suggests that dystrogly-
can is involved in organizing many basement membranes.
Laminin-1 and laminin-2 bind strongly to a-dystroglycan
(24), suggesting that this interaction provides the main linkage
of the DGC to basement membranes. Mutations in the gene
coding for the a2 subunit of laminin result in severe muscular
dystrophies (25–27). Moreover, antibodies directed against
laminin and a-dystroglycan perturb development of kidney (28,
29).
As a first step toward identifying possible functions of the
non-AChR-aggregating agrin isoform agrinA0B0, we have inves-
tigated its binding to a-dystroglycans isolated from different
tissues. We find that agrinA0B0 binds to a-dystroglycan isolated
from adult chick lung, kidney, and skeletal muscle with a
dissociation equilibrium constant of ; 2 nM. Binding to a-dys-
troglycan from adult chick brain was approximately 2-fold
lower. In addition, agrin co-localized with b-dystroglycan in
developing chicken kidney and lung. In conclusion, these data
provide evidence that agrin and a-dystroglycan bind strongly to
each other outside of the NMJ, suggesting that agrin may have
a similar function as the laminins in linking the basement
membrane to the DGC.
EXPERIMENTAL PROCEDURES
Protein Purification, Labeling, and Immunoprecipitations—A
95-kDa COOH-terminal agrin fragment, c95A0B0, expressed in COS-7 or
293 cells was purified by immunoaffinity column as described (6) using
the monoclonal antibody 5B1 (13). Agrin fragments were iodinated as
described elsewhere (30). Purification of a-dystroglycan was carried out
* This work was supported by Grant 31-33697.92 from the Swiss
National Science Foundation and by the Swiss Foundation for Research
on Muscle Diseases and the Rentenanstalt/Swiss Life. The costs of
publication of this article were defrayed in part by the payment of page
charges. This article must therefore be hereby marked “advertisement”
in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
§ Present address: The Salk Institute MNL-O, 10010 North Torrey
Pines Rd., La Jolla, CA 92037.
¶ These authors contributed equally to this work.
** To whom correspondence should be addressed: Dept. of Pharma-
cology, Biozentrum, University of Basel, Klingelbergstrasse 70, CH-
4056 Basel, Switzerland. Tel.: 41-61-267-2246 or 41-61-267-2213; Fax:
41-61-267-2208; E-mail: rueegg@ubaclu.unibas.ch.
1 The abbreviations used are: NMJ, neuromuscular junctions;
AChR(s), acetylcholine receptors; DGC, dystrophin-glycoprotein com-
plex; PAGE, polyacrylamide gel electrophoresis; PBS, phosphate-buff-
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as described elsewhere (31) with the following modifications: about 15 g
of freshly frozen tissue was homogenized in 40 ml of 50 mM Tris-HCl,
pH 7.5 containing 0.2 M NaCl and 1 mM phenylmethylsulfonyl fluoride
(buffer A) and incubated overnight with 10 ml of DEAE-Sephacel (Phar-
macia Biotech Inc.). The resin was washed three times with 30 ml of
buffer A, and bound proteins were eluted from the Sephacel with 20 ml
of 50 mM Tris-HCl, pH 7.5, and 0.5 M NaCl (buffer B). The eluate was
incubated with 2 ml of wheat germ agglutinin-Sepharose. After three
washes with 20 ml of buffer B, elution from wheat germ agglutinin-
Sepharose was achieved by adding 0.3 M N-acetylglucosamine. Eluted
proteins were then dialyzed against 25 mM Tris-HCl, 137 mM NaCl, 2.7
mM KCl, pH 7.4 (TBS) and concentrated using Centricon™ filters (Ami-
con). For immunoprecipitations, 5 g of freshly frozen tissue was homog-
enized in 20 ml of buffer A containing 1% Triton X-100. After centrif-
ugation at 39,000 3 g for 15 min, the supernatant was passed through
a filter paper. 750 ml of this filtrate was subjected to immunoprecipita-
tions using 4 ml of anti-agrin antiserum (32). After incubation overnight
at 4 °C, immunocomplexes were precipitated with protein A-Sepharose
as described elsewhere (6). The presence of b-dystroglycan in the im-
munoprecipitates was analyzed by SDS-PAGE followed by Western blot
analysis.
SDS-PAGE and Immunoblotting—Adult chicken tissues (about 1 g)
were homogenized on ice with a 15-ml Dounce homogenizer in 10 ml of
PBS containing a mixture of protease inhibitors (32). Homogenized
tissues were subjected to SDS-PAGE on a 3–12% gradient gel. Proteins
(;80 mg/lane) were transferred to nitrocellulose membranes as de-
scribed elsewhere (33). In agrin blots the transfer was carried out in the
absence of methanol. After blotting, membranes were washed once with
water and then blocked with PBS containing 3% milk powder and
0.05% Tween 20 (PBSM/T) for 2 h. Agrin immunoreactivity was detected
by incubating blots with the anti-agrin antiserum raised against recom-
binant chick agrin (32) at a dilution of 1:2,000 in PBSM/T. b-Dystrogly-
can was detected by the monoclonal antibody 8D5 (NovoCastra; Ref.
34), diluted 1:20 in PBSM/T. Incubation time for both reactions was 90
min at room temperature. Nitrocellulose membranes were washed
three times with PBSM/T and then subjected to a 45-min incubation with
appropriate horseradish peroxidase-conjugated secondary antibodies at
a dilution recommended by the manufacturer (Jackson ImmunoRe-
search Laboratories). After three washes with PBSM/T and one wash
with PBS, immunoreactive protein bands were visualized by the ECL
detection method (Amersham Corp.).
Transfer Overlay and Solid-phase Radioligand Binding Assays—
Transfer overlay assays were done as described (30). Solid-phase radio-
ligand binding assays were based on a protocol described in (30) with
minor modifications. Briefly, a-dystroglycan was immobilized on micro-
titer plates by overnight incubation at 4 °C in 50 mM sodium bicarbon-
ate, pH 9.6. Remaining binding sites were saturated by a 1-h incubation
with TBS containing 1.25 mM CaCl2, 1 mM MgCl2 (TBS
1Ca/1Mg) and 3%
BSA. After blocking, wells were incubated with 125I-c95A0B0 at room
temperature for 3 h in TBS1Ca/1Mg containing 3% BSA. The wells were
washed four times with TBS1Ca/1Mg, and bound radioactivity was
counted with a g counter. Each data point represents the average of
triplicate wells 6 S.D. Unspecific binding (binding in the presence of 2
mM unlabeled c95A0B0) was subtracted from each data point. Curves
were fitted by nonlinear regression analysis, assuming a single class of
equivalent binding sites, using the equation counts/min 5 (P 3 c/(Kd 1
c)), where counts/min represents radioactivity, Kd the binding dissoci-
ation constant, c the concentration of 125I-c95A0B0, and P counts/min at
saturation.
Immunofluorescence—Staining of frozen sections (12 mm) from em-
bryonic chicken lung or kidney were done as follows. Tissues were
cryoprotected by embedding them in PBS containing 20% sucrose before
they were frozen in Tissue-Tek (Miles). Unfixed cryostat sections were
blocked with PBS containing 3% BSA and 5% normal goat serum for 1 h
and incubated with diluted (1:2,000) anti-agrin antibodies (32) for 1 h.
After four washes with PBS, agrin immunoreactivity was visualized
using Cy3-conjugated secondary antibody (Jackson ImmunoResearch
Laboratories) at a dilution of 1:1,000. b-Dystroglycan immunoreactivity
in lung was detected by subsequent incubation of blocked slices with the
monoclonal antibody 8D5 (NovoCastra; Ref. 34) followed by incubation
with biotinylated secondary antibodies (Jackson ImmunoResearch Lab-
oratories) for 1 h. Conditioned medium from the hybridoma 8D5 was
diluted 2-fold, whereas the biotinylated secondary antibodies were used
at a dilution of 1:1,000. After four washes with PBS, sections were
incubated with fluorescein isothiocyanate-conjugated streptavidin for
45 min and again washed four times with PBS. b-Dystroglycan in
kidney slices was stained by a slightly different protocol. Sections were
blocked with PBS containing 5% BSA, followed by a 1-h incubation with
the monoclonal antibody 8D5. After four washes with PBS, goat anti-
mouse IgG (Jackson ImmunoResearch Laboratories) at a dilution of
1:1,000 were added for 45 min. b-Dystroglycan immunoreactivity was
then visualized using Cy3-conjugated rabbit anti-goat IgG (1:1,000;
Jackson ImmunoResearch Laboratories). After antibody incubation,
slices were again washed, mounted on glass coverslips with Citifluor
(City University), and analyzed under a Leica microscope equipped
with epifluorescence optics.
RESULTS
As a first step we analyzed the tissue distribution of agrin
and one of its binding proteins, a-dystroglycan, in the adult
chick. To this end, homogenates of brain, skeletal muscle, kid-
ney, lung, and liver were separated by SDS-PAGE, blotted to
nitrocellulose, and assayed for agrin and b-dystroglycan immu-
noreactivity by Western blot analysis. As shown in Fig. 1,
agrin-like immunoreactivity with an apparent molecular mass
between 400 and 600 kDa, was clearly detected in lung, kidney,
and brain whereas no signal was seen in skeletal muscle and
liver homogenates. Upon longer exposure agrin-like immuno-
reactivity with the high molecular mass could also be detected
in skeletal muscle while we were not able to detect it in liver
homogenates (data not shown). The tissue distribution of agrin
in adult chicken brain, liver, and skeletal muscle is similar to
that observed in the embryo, except that lower levels were
detected in adult skeletal muscle (32). One explanation for this
may be that in adult muscle, agrin expression is restricted to
the NMJ (8, 13). Agrin-like immunoreactivity was also associ-
ated with discrete bands around 100 kDa. Proteins of similar
size were purified from the electric organ of T. californica (35)
FIG. 1. Agrin and dystroglycan are expressed in a variety of
chick tissues. Proteins were separated on a 3–12% SDS-polyacryl-
amide gradient gel and incubated with an anti-agrin antiserum (32) or
the monoclonal anti-b-dystroglycan antibody 8D5 (34). In each lane, the
same amount of protein was loaded. Agrin and b-dystroglycan are
highly expressed in lung, kidney, and brain. Only a little agrin is found
in skeletal muscle. In liver only some immunoreactive protein with a
low Mr is detected. These immunoreactive bands with a lower Mr most
likely represent proteolytic degradation products of agrin. b-Dystrogly-
can is highly expressed in skeletal muscle but is not detected in liver.
No immunoreactive proteins were detected with the preimmune sera
(not shown). Molecular masses of standard proteins in kilodaltons are
given.
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and were also observed in embryonic chick and rat tissue (32,
36). These bands may represent proteolytic fragments derived
from full-length agrin.
Since no antibodies are available that reliably recognize
a-dystroglycan from chicken, we probed the same homogenates
for the presence of b-dystroglycan, which is derived from the
same precursor molecule and forms a tight complex with a-dys-
troglycan (19). As shown in Fig. 1, b-dystroglycan was most
abundant in brain, followed by lung, kidney,and skeletal mus-
cle, but b-dystroglycan was not detected in liver homogenates.
Hence, the amount of b-dystroglycan in these tissues correlates
with that of agrin except in skeletal muscle where b-dystrogly-
can was very abundant, but only a little agrin-like immunore-
activity was found.
Because lung, kidney,and muscle mainly express agrin tran-
scripts encoding the splice variant lacking inserts at sites A
and B (agrinA0B0; Refs. 7, 8, 11, and 12), we next determined
whether agrinA0B0 binds to a-dystroglycan isolated from these
tissues. To this end, binding of agrinA0B0 to a-dystroglycan
preparations isolated from a variety of tissues was analyzed by
transfer overlay assays. As ligands, we used either iodinated
full-length agrin (cAgrin7A0B0) or the 95-kDa COOH-terminal
fragment, c95A0B0 (see Ref. 32 for nomenclature). As shown in
Fig. 2, a-dystroglycan from all the tissues, except liver, gave a
strong binding signal. No difference in a-dystroglycan binding
was observed using recombinant full-length chick agrin
(cAgrin7A0B0) or its COOH-terminal half (c95A0B0; Fig. 2), in-
dicating that the NH2-terminal part of agrin does not substan-
tially contribute to the binding. While a-dystroglycan from
lung, kidney, and skeletal muscle had an apparent molecular
mass of 180 kDa, a-dystroglycan from brain was substantially
smaller. Differences in the Mr of a-dystroglycan have been
observed by others using laminin-1 as a ligand (31, 37, 38).
Since the predicted molecular mass of the a-dystroglycan core
protein is much smaller (;74 kDa; Ref. 19), the difference is
most likely due to its extensive post-translational glycosylation
(15, 38–40). The signals on transfer overlay assays were de-
tected with as little as 2.5 nM iodinated ligand, suggesting a
high-affinity binding of agrin to a-dystroglycan from all the
tissues examined.
Since transfer overlay assays do not allow accurate measure-
ment of binding affinity, we used radioligand binding assays to
determine equilibrium constants for the binding of recombi-
nant 125I-c95A0B0 to immobilized a-dystroglycan. As shown in
Fig. 3, binding of c95A0B0 to a-dystroglycan from skeletal mus-
cle, lung, kidney, and brain was detected at low nanomolar
concentrations. We measured Kd values between 2 and 5 nM
(Table I), demonstrating that agrinA0B0 binds to a-dystroglycan
with high affinity. Binding of 125I-c95A0B0 to a-dystroglycan
from all tissues was Ca21-dependent and was competed to
more than 90% with 2 mM unlabeled c95A0B0 (data not shown).
The approximately 2-fold higher Kd for brain-derived a-dystro-
glycan is most likely due to its different glycosylation. In this
context it is interesting to note that the binding of laminin-1
and laminin-2 to a-dystroglycan involves the carbohydrate moi-
ety of a-dystroglycan (39–41).
Our data strongly suggest that agrin is a high-affinity bind-
ing partner for a-dystroglycan in kidney and lung. To see
whether a-dystroglycan is associated with agrin in situ, we
next tested the a-dystroglycan preparations from lung and
kidney for the presence of agrin-like protein by Western blot
analysis. As shown in Fig. 4A, agrin-like immunoreactivity was
indeed detected in these preparations, but it had a reduced
apparent molecular mass compared with agrin detected in tis-
sue homogenates (see Fig. 1). As the binding site for dystrogly-
can is localized in the COOH-terminal part of agrin (see Fig. 2),
the lower Mr of agrin found in a-dystroglycan preparations may
be due to proteolytic cleavage within the amino-terminal por-
tion of the molecule. Cleavage within this region would release
a fragment that lacks the NtA domain of agrin, which is re-
sponsible for the binding of agrin to laminins (42). As the
binding of agrin to laminin is of high affinity (42), proteolytic
degradation may be requisite to extract agrin from tissue under
the mild conditions used to purify a-dystroglycan. To assure
that the presence of agrin-like immunoreactivity in the a-dys-
troglycan preparation reflected an association of both mole-
cules in situ, we tested whether immunoprecipitation with
anti-agrin antibodies from total tissue homogenates would also
enrich for b-dystroglycan. As shown in Fig. 4B, b-dystroglycan
was indeed present in these immunoprecipitations. These ex-
periments thus show that agrin and a-dystroglycan are asso-
ciated with each other in situ in adult kidney and lung.
To see whether agrin and dystroglycan could interact with
each other during development, we next stained consecutive
sections with anti-agrin or anti-b-dystroglycan antibodies. As
shown in Fig. 5, agrin-like immunoreactivity was highly con-
centrated in basement membranes of lung bronchioles and
kidney tubules. At the light microscopic level, b-dystroglycan
FIG. 2. Transfer overlay assays with
agrinA0B0 to detect a-dystroglycans
from different chick tissues. Proteins
were separated on a 6% SDS-PAGE, blot-
ted to nitrocellulose, and overlaid either
with a 95-kDa iodinated agrin fragment
(125I-c95A0B0 (A)) or full-length chick
agrin (125I-cAgrin7A0B0 (B)). Each lane
was incubated with 2.5 nM iodinated
agrin. Origin of a-dystroglycan prepara-
tion is indicated. Molecular masses of
marker proteins in kilodaltons are shown.
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showed the same tissue distribution (Fig. 5, right column). No
staining was detected with an agrin preimmune serum or in
the absence of the b-dystroglycan antibody (data not shown). In
summary, these data indicate that agrin and a-dystroglycan
may also interact with each other during kidney and lung
development.
DISCUSSION
Previous work on the binding of agrin and dystroglycan dealt
mainly with the functional consequences of this interaction in
the formation of the NMJ. It has been shown that the agrin
isoform lacking inserts at sites A and B (agrinA0B0), which is
inactive in AChR aggregation, binds to skeletal muscle a-dys-
troglycan with higher affinity than the AChR-aggregating iso-
form agrinA4B8 (18, 30, 43). Moreover, the region of agrin suf-
ficient for AChR aggregation is distinct from the binding site
for a-dystroglycan, making it unlikely that the binding of agrin
to a-dystroglycan is involved in the signaling mechanisms ini-
tiated by agrin (30, 43).
In a solid-phase radioligand binding assay agrinA0B0 binds to
skeletal muscle a-dystroglycan with a dissociation constant of
less than 2 nM (Table I). Using the same binding assay, a Kd
value of 8 nM was determined for laminin-1 and a mixture of
laminin-2 and laminin-4 (24). Hence, agrin seems to bind to
muscle a-dystroglycan with higher affinity than the laminins.
We also noticed this difference in the binding affinities in
inhibition experiments. While an excess of unlabeled agrinA0B0
was always very efficient in inhibiting the binding of iodinated
laminin-1 to a-dystroglycan, the same concentration of unla-
beled laminin-1 inhibited the binding of iodinated agrinA0B0
only partially.2
In mature muscle fibers, agrin is concentrated at the NMJ
and only little is detected in extrasynaptic regions (Fig. 1; Refs.
8 and 13). Agrin is therefore unlikely to be the major binding
partner of a-dystroglycan in muscle fibers outside of the NMJ;
instead, laminin-2 may have this role. The situation may, how-
ever, be different in adult kidney and lung, where agrin is
expressed at high levels (Fig. 1). Lung and kidney, like muscle
fibers, express transcripts encoding agrinA0B0 (11, 12). Our
2 M. Gesemann and M. A. Ruegg, unpublished observation.
FIG. 3. Solid-phase radioligand binding of agrinA0B0 to a-dystroglycans. Purified a-dystroglycan was coated to microtiter plates, blocked
by 3% BSA, and incubated with iodinated agrinA0B0. The tissue source of the a-dystroglycans is indicated. Curves were fitted by nonlinear
regression analysis as described under “Experimental Procedures.” To allow comparison of the binding curves from different tissues, data were
normalized to the fitted value for radioactivity at total saturation. In addition, unspecific binding (i.e. binding in the presence of 2 mM unlabeled
c95A0B0) at each data point was subtracted. Data shown are the result of one representative experiment. Each value represents the mean 6 S.D.
of three measurements.
TABLE I
Dissociation binding constants of agrin to a-dystroglycans
Solid-phase radioligand binding was used to assess the affinity of
agrin (c95A0B0) to coated a-dystroglycan (see also Fig. 3). Experiments
were performed at room temperature in TBS containing 1.25 mM CaCl2
and 1 mM MgCl2. At least three independent measurements were used
to calculate individual dissociation constants.
a-Dystroglycan preparation (tissue) Kd values 6 S.E.
nM
Lung 2.2 6 0.8
Kidney 1.9 6 0.7
Skeletal muscle 1.8 6 0.3
Brain 4.6 6 0.7
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study now shows that agrinA0B0 binds to a-dystroglycan from
both tissues with high affinity (Kd values ;2 nM) and that agrin
is complexed with dystroglycan in vivo (Figs. 4 and 5). Hence,
the major binding protein for a-dystroglycan in adult kidney
and lung may be agrin and not the laminins.
In kidney, the binding of laminin-1 to a-dystroglycan has
been suggested to be important during epithelial morphogene-
sis. This is mainly based on perturbation studies using poly-
clonal antibodies directed against proteolytic fragments E8 or
E3 of laminin-1 (28) or the function-blocking monoclonal anti-
body IIH6 directed against a-dystroglycan (29). In those stud-
ies, the antibodies perturbed the differentiation of mesenchyme
into epithelium in organ cultures of embryonic kidneys. Here
we show co-localization of b-dystroglycan and agrin in devel-
oping chick kidney tubules and lung bronchioles (Fig. 5). Al-
though we used anti-b-dystroglycan antibodies instead of anti-
a-dystroglycan antibodies, it is likely that the tissue
distribution of the two proteins does not differ. Both proteins
originate from the same precursor molecule (19), they tightly
associate with each other, and in other species, no differences
in the tissue distribution of a- and b-dystroglycan have been
observed. We therefore conclude that agrin is highly expressed
in developing chick kidney and lung and that it co-distributes
with a-dystroglycan. This co-localization hence suggests that
binding of agrin to a-dystroglycan may also be possible during
embryogenesis. Although we have not looked at the tissue
distribution of agrin and a-dystroglycan at early stages of kid-
ney and lung development, we hypothesize that part of the
perturbation of kidney development with the monoclonal anti-
body IIH6 (29) might be due to inhibition of the agrin-dystro-
glycan interaction. Hence, it would be interesting to study the
effect of anti-agrin antibodies on the development of kidney.
We have also determined the binding affinity of agrinA0B0 to
a-dystroglycan isolated from adult brain. We find that this
binding is of more than 2-fold lower affinity than that to a-dys-
troglycan from skeletal muscle, kidney, and lung (Table I). The
weaker binding of agrin is paralleled by a decrease in the
apparent Mr of brain a-dystroglycan, suggesting an involve-
ment of carbohydrates in the binding (37, 44). Consistent with
this, glycosylation of a-dystroglycan is critically involved in the
binding of laminin-1 (39–41). Again, the functional signifi-
cance of the binding of agrin to brain-derived a-dystroglycan is
not yet clear. Agrin-like immunoreactivity in the brain is
highly concentrated in the basal lamina of certain microvessels
that serve as selective filtration barriers. The endothelial cells
lining the blood capillaries express the splice variant agrinA0B0,
which binds most strongly to a-dystroglycan (12). Blood capil-
laries in the nervous system also express a-dystroglycan, utro-
phin, and a2 chain-containing laminins (45–47). The presence
of agrin and dystroglycan in blood capillaries and the finding
that agrin expression is high when a functional blood-brain
barrier is established (48) suggest a role of the dystroglycan-
agrin binding in blood-brain barrier formation. Alternatively,
the binding of agrin to a-dystroglycan may play a role in the
maintenance of synaptic structures as DGC-like immunoreac-
tivity is detected at synapses in the central nervous system (47,
49). Similarly, agrin-like immunoreactivity has been found at
synapses in the chick retina (50).
No gross abnormalities in the tissues examined here have
been reported in the agrin-deficient mice (2). In these knockout
mice, only the exons encoding site B were removed. As a con-
sequence, even in homozygous knockout animals, agrin iso-
forms lacking the B-site were still expressed, although at a
FIG. 4. Agrin is complexed with a-dystroglycan in situ. A, West-
ern blot analysis using anti-agrin antibodies on a-dystroglycan purified
from lung and kidney. No immunoreactive proteins were detected with
an agrin preimmune serum (not shown). B, b-dystroglycan co-immuno-
precipitates with agrin from adult lung and kidney. Western blot anal-
ysis using anti-b-dystroglycan antibodies on tissue extracts that had
been precipitated with preimmune serum (pre-IS) or anti-agrin anti-
serum (a-agrin). As a control, total extract (extract) was included. In
lung and kidney, b-dystroglycan is enriched in the agrin immunopre-
cipitates, while no specific signal is seen using preimmune serum. The
band with a slightly higher molecular mass than b-dystroglycan, also
seen with preimmune serum, represents cross-reactivity of the second-
ary antibody with the heavy chain of rabbit IgG. The blots using tissue
extracts were exposed seven times longer than serum-treated samples.
SDS-PAGE in all cases was 3–12% polyacrylamide gradient gels. Mo-
lecular masses in kilodaltons of standard proteins are given.
FIG. 5. Immunolocalization of agrin and b-dystroglycan dur-
ing development of chick lung and kidney. Consecutive frozen
sections of 15-day-old embryonic kidney and lung were stained either
with anti-agrin or anti-b-dystroglycan antibodies as indicated. Both
agrin and b-dystroglycan are localized in the basement membranes of
developing kidney tubules or lung bronchioles. Bars 5 50 mm.
Non-muscle a-Dystroglycan Binds to Agrin604
 at H
auptbibliothek Universitaet Zuerich Irchel. Bereich Forschung on July 24, 2007 
w
w
w
.jbc.org
D
ow
nloaded from
 
much lower level. As the binding affinity of agrin to a-dystro-
glycan is high, the low level of agrin may have been sufficient
for a functional interaction with a-dystroglycan. Animals that
are completely deficient in agrin may be required to reveal the
functional consequences of the loss of the binding of agrin to
a-dystroglycan.
Acknowledgments—We are grateful to Micarna SA, in particular to
Mr. Carquillat, for providing us with fresh chick tissue. We thank Dr. J.
Engel for many helpful discussions during the course of this work. We
are grateful to Drs. A. J. Denzer and R. A. Kammerer for their sugges-
tions and to D. M. Hauser and Dr. W. B. Adams for reading the
manuscript.
REFERENCES
1. McMahan, U. J. (1990) Cold Spring Harb. Symp. Quant. Biol. 55, 407–418
2. Gautam, M., Noakes, P. G., Moscoso, L., Rupp, F., Scheller, R. H., Merlie, J. P.,
and Sanes, J. R. (1996) Cell 85, 525–535
3. Wallace, B. G. (1989) J. Neurosci. 9, 1294–1302
4. Ruegg, M. A., Tsim, K. W., Horton, S. E., Kro¨ger, S., Escher, G., Gensch, E. M.,
and McMahan, U. J. (1992) Neuron 8, 691–699
5. Ferns, M. J., Campanelli, J. T., Hoch, W., Scheller, R. H., and Hall, Z. (1993)
Neuron 11, 491–502
6. Gesemann, M., Denzer, A. J., and Ruegg, M. A. (1995) J. Cell Biol. 128,
625–636
7. McMahan, U. J., Horton, S. E., Werle, M. J., Honig, L. S., Kroger, S., Ruegg,
M. A., and Escher, G. (1992) Curr. Opin. Cell Biol. 4, 869–874
8. Hoch, W., Ferns, M., Campanelli, J. T., Hall, Z. W., and Scheller, R. H. (1993)
Neuron 11, 479–490
9. Thomas, W. S., O’Dowd, D. K., and Smith, M. A. (1993) Dev. Biol. 158, 523–535
10. Smith, M. A., and O’Dowd, D. K. (1994) Neuron 12, 795–804
11. Ma, E., Morgan, R., and Godfrey, E. W. (1994) J. Neurosci. 14, 2943–2952
12. Stone, D. M., and Nikolics, K. (1995) J. Neurosci. 15, 6767–6778
13. Reist, N. E., Magill, C., and McMahan, U. J. (1987) J. Cell Biol. 105,
2457–2469
14. Godfrey, E. W. (1991) Exp. Cell Res. 195, 99–109
15. Bowe, M. A., Deyst, K. A., Leszyk, J. D., and Fallon, J. R. (1994) Neuron 12,
1173–1180
16. Gee, S. H., Montanaro, F., Lindenbaum, M. H., and Carbonetto, S. (1994) Cell
77, 675–686
17. Campanelli, J. T., Roberds, S. L., Campbell, K. P., and Scheller, R. H. (1994)
Cell 77, 663–674
18. Sugiyama, J., Bowen, D. C., and Hall, Z. W. (1994) Neuron 13, 103–115
19. Ibraghimov-Beskrovnaya, O., Ervasti, J. M., Leveille, C. J., Slaughter, C. A.,
Sernett, S. W., and Campbell, K. P. (1992) Nature 355, 696–702
20. Henry, M. D., and Campbell, K. P. (1996) Curr. Opin. Cell Biol. 8, 625–631
21. Campbell, K. P. (1995) Cell 80, 675–679
22. Worton, R. (1995) Science 270, 755–756
23. Williamson, R. A., Henry, M. D., Daniels, K. J., Hrstka, R. F., Lee, J. C.,
Sunada, Y., Ibraghimov-Beskrovnaya, O., and Campbell, K. P. (1997) Hum.
Mol. Genet. 6, 831–841
24. Pall, E. A., Bolton, K. M., and Ervasti, J. M. (1996) J. Biol. Chem. 271,
3817–3821
25. Tome, F. M., Evangelista, T., Leclerc, A., Sunada, Y., Manole, E., Estournet,
B., Barois, A., Campbell, K. P., and Fardeau, M. (1994) C. R. Seances Acad.
Sci. Ser. III 317, 351–357
26. Hillaire, D., Leclerc, A., Faure, S., Topaloglu, H., Chiannilkulchai, N.,
Guicheney, P., Grinas, L., Legos, P., Philpot, J., Evangelista, T., Routon,
M.-C., Mayer, M., Pellisier, J.-F., Estournet, B., Barois, A., Hentati, F.,
Feingold, N., Beckmann, J. S., Dubowitz, V., Tome, F. M. S., and Fardeau,
M. (1994) Hum. Mol. Genet. 3, 1657–1661
27. Helbling-Leclerc, A., Zhang, X., Topaloglu, H., Cruaud, C., Tesson, F.,
Weissenbach, J., Tome´, F. M. S., Schwartz, K., Fardeau, M., Tryggvason, K.,
and Guicheney, P. (1995) Nat. Genet. 11, 216–218
28. Klein, G., Langegger, M., Timpl, R., and Ekblom, P. (1988) Cell 55, 331–341
29. Durbeej, M., Larsson, E., Ibraghimov-Beskrovnaya, O., Roberds, S. L.,
Campbell, K. P., and Ekblom, P. (1995) J. Cell Biol. 130, 79–91
30. Gesemann, M., Cavalli, V., Denzer, A. J., Brancaccio, A., Schumacher, B., and
Ruegg, M. A. (1996) Neuron 16, 755–767
31. Brancaccio, A., Schulthess, T., Gesemann, M., and Engel, J. (1995) FEBS Lett.
368, 139–142
32. Denzer, A. J., Gesemann, M., Schumacher, B., and Ruegg, M. A. (1995) J. Cell
Biol. 131, 1547–1560
33. Towbin, H., Staehelin, T., and Gordon, J. (1979) Proc. Natl. Acad. Sci. U. S. A.
76, 4350–4354
34. Bewick, G. S., Nicholson, L. V., Young, C., and Slater, C. R. (1993)
Neuromuscul. Disord. 3, 503–506
35. Nitkin, R. M., Smith, M. A., Magill, C., Fallon, J. R., Yao, Y.-M. M., Wallace,
B. G., and McMahan, U. J. (1987) J. Cell Biol. 105, 2471–2478
36. Rupp, F., Payan, D. G., Magill-Solc, C., Cowan, D. M., and Scheller, R. H.
(1991) Neuron 6, 811–823
37. Gee, S. H., Blacher, R. W., Douville, P. J., Provost, P. R., Yurchenco, P. D., and
Carbonetto, S. (1993) J. Biol. Chem. 268, 14972–14980
38. Smalheiser, N. R., and Kim, E. (1995) J. Biol. Chem. 270, 15425–15433
39. Ervasti, J. M., and Campbell, K. P. (1993) J. Cell Biol. 122, 809–823
40. Chiba, A., Matsumura, K., Yamada, H., Inazu, T., Shimizu, T., Kusunoki, S.,
Kanazawa, I., Kobata, A., and Endo, T. (1997) J. Biol. Chem. 272,
2156–2162
41. Yamada, H., Chiba, A., Endo, T., Kobata, A., Anderson, V. B., Hori, H.,
Fukuta-Ohi, H., Kanazawa, I., Campbell, K. P., Shimizu, T., and
Matsumura, K. (1996) J. Neurochem. 66, 1518–1524
42. Denzer, A. J., Brandenberger, R., Gesemann, M., Chiquet, M., and Ruegg,
M. A. (1997) J. Cell Biol. 137, 671–683
43. Hopf, C., and Hoch, W. (1996) J. Biol. Chem. 271, 5231–5236
44. Smalheiser, N. R. (1993) J. Neurosci. Res. 36, 528–538
45. Khurana, T. S., Watkins, S. C., and Kunkel, L. M. (1992) J. Cell Biol. 119,
357–366
46. Montanaro, F., Carbonetto, S., Campbell, K. P., and Lindenbaum, M. (1995)
J. Neurosci. Res. 42, 528–538
47. Tian, M., Jacobson, C., Gee, S. H., Campbell, K. P., Carbonetto, S., and Jucker,
M. (1996) Eur. J. Neurosci. 8, 2739–2747
48. Barber, A. J., and Lieth, E. (1997) Dev. Dyn. 208, 62–74
49. Lidov, H. G., Byers, T. J., Watkins, S. C., and Kunkel, L. M. (1990) Nature 348,
725–728
50. Mann, S., and Kro¨ger, S. (1996) Mol. Cell. Neurosci. 8, 1–13
Non-muscle a-Dystroglycan Binds to Agrin 605
 at H
auptbibliothek Universitaet Zuerich Irchel. Bereich Forschung on July 24, 2007 
w
w
w
.jbc.org
D
ow
nloaded from
 
